BI
BICX.US BioCorRx Inc
- Market cap
- USD 6.01M
- P/E
- -
- P/B
- 209.37x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BICX.US undervalued?
Graham numberThe Graham number of BioCorRx Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioCorRx Inc fundamental analysis
No fundamental analysis for BioCorRx Inc yet.
BioCorRx Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioCorRx Inc
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. The company offers a substance use disorder recovery program, Beat Addiction Recovery, which includes cognitive behavioral therapy modules, peer support through a mobile application, and medication prescription from an independent treating physician; and the UnCraveRx weight loss management program, a medication-assisted weight los…
Full company profileBioCorRx Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioCorRx Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 702K | 657K | 377K | 240K | 123K | 48.3K | 214K | 89.2K | 7.67K | 797K | 605K |
| Gross Profit | 526K | 334K | 206K | 159K | 123K | 42.4K | 199K | 53.2K | 6.00K | 775K | 265K |
| Operating Income | -2.05M | -2.89M | -4.38M | -4.47M | -7.49M | -4.53M | -2.91M | -2.81M | -3.65M | -2.40M | -2.75M |
| EBITDA | - | -2.86M | -4.37M | -4.37M | -2.86M | -4.48M | -3.15M | -2.68M | -3.59M | -2.56M | -2.97M |
| Net Income | -5.90M | -29.7M | -6.51M | -6.04M | -3.51M | -5.21M | -4.37M | -3.77M | -5.11M | -3.44M | -3.59M |
| EPS | - | -12 | -2.51 | -1.13 | -0.64 | -0.78 | -0.57 | -0.43 | -0.38 | -0.14 | -0.12 |
| Balance Sheet | |||||||||||
| Total Assets | 470K | 339K | 628K | 3.93M | 1.83M | 820K | 767K | 389K | 386K | 2.15M | 1.91M |
| Total Liabilities | 8.60M | 4.23M | 6.33M | 4.99M | 6.04M | 7.78M | 8.97M | 10.3M | 12.7M | 13.7M | 14.4M |
| Shareholders' Equity | -8.13M | -3.89M | -5.71M | -1.06M | -4.21M | -6.96M | -8.08M | -9.82M | -12.1M | -11.2M | -12.2M |
| Cash & Short-term Investments | 92.5K | 11.3K | 280K | 2.65M | 592K | 85.8K | 68.6K | 65.2K | 88.0K | 139K | 21.2K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.00M | -2.54M | -1.83M | -2.94M | -2.15M | -3.54M | -2.04M | -1.85M | -1.10M | -2.30M | -1.75M |
| Capital Expenditure | 328K | 2.97K | 30.7K | 123K | 9.23K | 2.02K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -2.54M | -1.88M | -3.06M | -2.16M | -3.59M | -2.04M | -1.85M | -1.10M | -2.30M | -1.75M |
| Ratios | |||||||||||
| ROA | -1,255.1% | -8,765.3% | -1,036.6% | -153.6% | -191.9% | -635.2% | -570.0% | -968.6% | -1,323.0% | -160.2% | -188.3% |
| Net Profit Margin | -841.3% | -4,519.5% | -1,728.9% | -2,513.8% | -2,859.6% | -10,789.4% | -2,043.3% | -4,224.9% | -66,616.1% | -431.5% | -593.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioCorRx Inc dividends
BioCorRx Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:100 on Jan 22, 2019.
Who owns BioCorRx Inc
- Insiders 59.91%
- Institutions 0.00%
- Public & others 40.09%
- Shares outstanding 29.8M
- Free float 12.1M
BioCorRx Inc company profile
- Company name
- BioCorRx Inc
- Ticker
- BICX.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- December
- Address
- 2390 East Orangewood Avenue, Anaheim, CA, United States, 92806
- Phone
- 714 462 4880
- Website
- biocorrx.com
About BioCorRx Inc
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. The company offers a substance use disorder recovery program, Beat Addiction Recovery, which includes cognitive behavioral therapy modules, peer support through a mobile application, and medication prescription from an independent treating physician; and the UnCraveRx weight loss management program, a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists. It also develops BICX101, an injectable and implantable naltrexone product; BICX102, a long-acting naltrexone implant that can last several months for opioid dependence and alcohol use disorders; and BICX104, a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder. The company licenses and distributes its program to healthcare providers and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. was founded in 2009 and is based in Anaheim, California.
BioCorRx Inc management
3- Mr. Louis Charles LucidoPresident & Chairman · born 1948
- Ms. Lourdes FelixCEO, CFO & Director · born 1968
- Dr. George N. FallierasMedical Consultant